Solid Organ Transplant Infections Quiz
24 Questions
1 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the incidence of donor-derived infections (DDIs) in solid organ transplantation in the United States?

  • Less than 1% (correct)
  • Around 5%
  • Around 10%
  • More than 15%

    • What are the most common viral infections in transplant patients?

  • Rotavirus, norovirus, adenovirus, and coronavirus
  • CMV, BK virus, EBV, and varicella zoster virus (correct)
  • Herpes simplex virus, human papillomavirus, measles virus, and mumps virus
  • HIV, HBV, HCV, and influenza virus

    • What is the most prevalent primary source of bacterial infection over 6 months post-transplant?

  • Respiratory tract infections
  • Skin and soft tissue infections
  • Gastrointestinal infections
  • Urinary tract infections (correct)

    • What are the risk factors for UTI in transplant patients?

    <p>Age, diabetes, and long-term use of a urinary indwelling catheter</p> Signup and view all the answers

    What is the recommended prophylactic treatment for Pneumocystis jirovecii pneumonia and UTIs in transplant patients?

    <p>TMP/SMZ</p> Signup and view all the answers

    What is the most effective approach to preventing CMV disease in liver transplant recipients?

    <p>Preemptive ganciclovir or valganciclovir</p> Signup and view all the answers

    What is the recommended prophylactic therapy for all lung transplant recipients?

    <p>CMV prophylaxis</p> Signup and view all the answers

    What is the association between Epstein Barr virus (EBV) and post-transplant lymphoproliferative disorder (PTLD)?

    <p>Greatly increased risk</p> Signup and view all the answers

    What is the most prevalent primary source of bacterial infection over 6 months post-transplant?

    <p>Urinary tract infections</p> Signup and view all the answers

    What is the recommended prophylaxis for mucocutaneous fungal infections in immunosuppressed transplant recipients?

    <p>High-dose fluconazole</p> Signup and view all the answers

    What is the most common viral infection in transplant patients?

    <p>Cytomegalovirus (CMV)</p> Signup and view all the answers

    What is the incidence of donor-derived infections (DDIs) in all transplant procedures in the United States?

    <p>Less than 1%</p> Signup and view all the answers

    Which prophylactic drug is commonly used for the prevention of Pneumocystis jirovecii pneumonia and UTIs?

    <p>TMP/SMZ</p> Signup and view all the answers

    What is the recommended prophylaxis for CMV infection in lung transplant recipients?

    <p>Oral valganciclovir</p> Signup and view all the answers

    What is the association between BK virus infection and renal transplant recipients?

    <p>Polyomavirus-associated nephropathy</p> Signup and view all the answers

    What is the best approach to preventing CMV disease in liver transplant recipients?

    <p>Preemptive therapy</p> Signup and view all the answers

    What is the most prevalent primary source of bacterial infection over 6 months post-transplant?

    <p>Urinary tract infections</p> Signup and view all the answers

    What is the most common viral infection in transplant patients?

    <p>Cytomegalovirus (CMV)</p> Signup and view all the answers

    What is the recommended prophylaxis for Pneumocystis jirovecii pneumonia and UTIs in transplant patients?

    <p>TMP/SMZ</p> Signup and view all the answers

    What is the treatment for post-transplant bacterial infections?

    <p>Drug therapy per guideline recommendation for that specific disease</p> Signup and view all the answers

    What is the most effective approach to preventing CMV disease in liver transplant recipients?

    <p>Preemptive therapy</p> Signup and view all the answers

    What is the recommended prophylaxis for all lung transplant recipients?

    <p>IV ganciclovir</p> Signup and view all the answers

    What is the association between BK virus infection and renal transplant recipients?

    <p>Associated with polyomavirus-associated nephropathy</p> Signup and view all the answers

    What is the risk associated with Epstein Barr virus (EBV) in EBV seronegative individuals?

    <p>Increased risk of post-transplant lymphoproliferative disorder (PTLD)</p> Signup and view all the answers

    Study Notes

    Infections in Solid Organ Transplantation: Prophylaxis and Treatment

    • Solid organ transplantation carries the risk of transmission of bacterial, viral, fungal, and parasitic infections.

    • Donor-derived infections (DDIs) occur in less than 1% of all transplant procedures in the United States.

    • The incidence of DDIs is low, but when transmission occurs, significant morbidity and mortality can result.

    • Common viral infections in transplant patients include cytomegalovirus (CMV), BK virus, Epstein Bar virus (EBV), and varicella (herpes) zoster virus.

    • Common bacterial infections in transplant patients include skin and soft tissue infections and urinary tract infections (UTIs).

    • UTIs are the most prevalent primary source of bacterial infection over 6 months post-transplant, with common pathogens such as E. coli, Enterococcus faecium, Klebsiella species, S. aureus, Enterobacter species, and Enterococcus faecalis.

    • Risk factors for UTI in transplant patients include age, diabetes, and long-term use of a urinary indwelling catheter.

    • Prophylactic use of TMP/SMZ for the prevention of Pneumocystis jirovecii pneumonia as well as UTIs is common, but UTIs are considered less preventable due to increasing rates of TMP/SMZ resistance.

    • Post-transplant bacterial infections are treated per guideline recommendation for that specific disease, with drug therapy streamlined when culture and sensitivity reports return.

    • Prophylactic oral or topical antifungal agents may be indicated for mucocutaneous fungal infections in immunosuppressed transplant recipients.

    • Liver, pancreas, and small bowel transplant recipients are at high risk for invasive fungal infections and should receive prophylaxis with fluconazole.

    • Prophylaxis with inhaled LAMB, high-dose fluconazole, itraconazole, voriconazole, and echinocandins have all been reported, but data supporting either the general recommendation for prophylaxis or choice of specific agent are largely lacking with center-to-center variability.Antiviral Prophylaxis and Management in Solid Organ Transplantation

    • Solid organ transplant recipients are at high risk for opportunistic infections, including toxoplasmosis, cytomegalovirus (CMV), BK virus, and Epstein Barr virus (EBV).

    • Patients receiving trimethoprim-sulfamethoxazole for P. jiroveci prophylaxis are also protected against T. gondii and N. asteroides.

    • Patients are advised to have their pets taken care of by others during the first 6 months to 1 year post-transplant to reduce the risk of toxoplasmosis.

    • Prophylaxis with IV ganciclovir or oral valganciclovir is effective in reducing the incidence of both primary and reactivated CMV infection.

    • Preemptive ganciclovir or valganciclovir, initiated after actual isolation of CMV from blood, urine, or other sites, is more effective than acyclovir in preventing CMV disease in liver transplant recipients.

    • Whether prophylaxis or preemptive therapy is the best approach to preventing CMV disease is controversial, with concerns about prolonged exposure to drugs leading to viral resistance.

    • Prophylactic therapy is recommended primarily in patients at highest risk of disease, while lower-risk patients are often recommended to receive only preemptive therapy.

    • Prophylaxis is routinely recommended for all lung transplant recipients due to the high risk of CMV infection and disease.

    • Oral valganciclovir is a suitable alternative to intravenous ganciclovir, with a comparable daily exposure of ganciclovir.

    • BK virus infection in renal transplant recipients is associated with viruria, viremia, and polyomavirus-associated nephropathy, and there is no accepted treatment other than reduction in immunosuppression.

    • Epstein Barr virus (EBV) is associated with greatly increased risk of post-transplant lymphoproliferative disorder (PTLD) in EBV seronegative individuals, with insufficient data to support routine use of antiviral prophylaxis.

    • Valganciclovir is recommended for CMV prophylaxis in patients with a high risk of infection, such as those with a CMV mismatch (donor positive, recipient negative), while other medications should be adjusted based on the individual patient's needs.

    Infections in Solid Organ Transplantation: Prophylaxis and Treatment

    • Solid organ transplantation carries the risk of transmission of bacterial, viral, fungal, and parasitic infections.

    • Donor-derived infections (DDIs) occur in less than 1% of all transplant procedures in the United States.

    • The incidence of DDIs is low, but when transmission occurs, significant morbidity and mortality can result.

    • Common viral infections in transplant patients include cytomegalovirus (CMV), BK virus, Epstein Bar virus (EBV), and varicella (herpes) zoster virus.

    • Common bacterial infections in transplant patients include skin and soft tissue infections and urinary tract infections (UTIs).

    • UTIs are the most prevalent primary source of bacterial infection over 6 months post-transplant, with common pathogens such as E. coli, Enterococcus faecium, Klebsiella species, S. aureus, Enterobacter species, and Enterococcus faecalis.

    • Risk factors for UTI in transplant patients include age, diabetes, and long-term use of a urinary indwelling catheter.

    • Prophylactic use of TMP/SMZ for the prevention of Pneumocystis jirovecii pneumonia as well as UTIs is common, but UTIs are considered less preventable due to increasing rates of TMP/SMZ resistance.

    • Post-transplant bacterial infections are treated per guideline recommendation for that specific disease, with drug therapy streamlined when culture and sensitivity reports return.

    • Prophylactic oral or topical antifungal agents may be indicated for mucocutaneous fungal infections in immunosuppressed transplant recipients.

    • Liver, pancreas, and small bowel transplant recipients are at high risk for invasive fungal infections and should receive prophylaxis with fluconazole.

    • Prophylaxis with inhaled LAMB, high-dose fluconazole, itraconazole, voriconazole, and echinocandins have all been reported, but data supporting either the general recommendation for prophylaxis or choice of specific agent are largely lacking with center-to-center variability.Antiviral Prophylaxis and Management in Solid Organ Transplantation

    • Solid organ transplant recipients are at high risk for opportunistic infections, including toxoplasmosis, cytomegalovirus (CMV), BK virus, and Epstein Barr virus (EBV).

    • Patients receiving trimethoprim-sulfamethoxazole for P. jiroveci prophylaxis are also protected against T. gondii and N. asteroides.

    • Patients are advised to have their pets taken care of by others during the first 6 months to 1 year post-transplant to reduce the risk of toxoplasmosis.

    • Prophylaxis with IV ganciclovir or oral valganciclovir is effective in reducing the incidence of both primary and reactivated CMV infection.

    • Preemptive ganciclovir or valganciclovir, initiated after actual isolation of CMV from blood, urine, or other sites, is more effective than acyclovir in preventing CMV disease in liver transplant recipients.

    • Whether prophylaxis or preemptive therapy is the best approach to preventing CMV disease is controversial, with concerns about prolonged exposure to drugs leading to viral resistance.

    • Prophylactic therapy is recommended primarily in patients at highest risk of disease, while lower-risk patients are often recommended to receive only preemptive therapy.

    • Prophylaxis is routinely recommended for all lung transplant recipients due to the high risk of CMV infection and disease.

    • Oral valganciclovir is a suitable alternative to intravenous ganciclovir, with a comparable daily exposure of ganciclovir.

    • BK virus infection in renal transplant recipients is associated with viruria, viremia, and polyomavirus-associated nephropathy, and there is no accepted treatment other than reduction in immunosuppression.

    • Epstein Barr virus (EBV) is associated with greatly increased risk of post-transplant lymphoproliferative disorder (PTLD) in EBV seronegative individuals, with insufficient data to support routine use of antiviral prophylaxis.

    • Valganciclovir is recommended for CMV prophylaxis in patients with a high risk of infection, such as those with a CMV mismatch (donor positive, recipient negative), while other medications should be adjusted based on the individual patient's needs.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Related Documents

    SOT7_ID_57 (1).pptx

    Description

    Test your knowledge on preventing and treating infections in solid organ transplant recipients with this informative quiz. Learn about the risk factors, common viral and bacterial infections, and prophylactic and therapeutic measures for various infections, including CMV, BK virus, EBV, and fungal infections. Explore the controversies surrounding prophylaxis vs. preemptive therapy and the use of antiviral agents in preventing post-transplant lymphoproliferative disorder. This quiz is a must-take for healthcare professionals involved in solid

    More Like This

    Solid Organ Transplantation Pharmacogenomics and Drug-Drug Interactions Quiz
    21 questions

    Solid Organ Transplantation Pharmacogenomics and Drug-Drug Interaction...

    DignifiedEnlightenment avatar
    DignifiedEnlightenment
    Solid Organ Transplantation
    29 questions

    Solid Organ Transplantation

    DignifiedEnlightenment avatar
    DignifiedEnlightenment
    Solid Organ Transplant Overview
    16 questions

    Solid Organ Transplant Overview

    SeamlessIambicPentameter864 avatar
    SeamlessIambicPentameter864
    Infecciones en Trasplantes de Órgano Sólido
    20 questions

    Infecciones en Trasplantes de Órgano Sólido

    GratifiedMotif avatar
    GratifiedMotif
    Use Quizgecko on...
    Browser
    Open
    Browser
    Browser